Company news
Rhythm Biosciences Limited (ASX:RHY) news
Rhythm Biosciences Limited news releases on 6ix. Latest, Oct 6, 2026: ColoSTAT Economic Study - Australian Public Health Savings
Press releases & updates
ColoSTAT Economic Study - Australian Public Health Savings
October 6, 2026
Initial ColoSTAT Assessment in UK opens new market access
September 21, 2026
FY26 Appendix 4E & Audited Financial Report
August 27, 2026
Response to ASX Query Letter
April 14, 2026
First ColoSTAT Clinical Test Sale
March 10, 2026
NATA Accredits ColoSTAT Clinical Testing Service
March 8, 2026
RHY Executes SE Asian Genetype Distribution Agreement
March 3, 2026
Exercise of RHYO Options underwritten for $4.5m to $6.0m
February 24, 2026
Trading Halt
February 22, 2026
Half-Year Financial Report and Appendix 4D
February 18, 2026
Rhythm Bio enters ColoSTAT agreement with 4Cyte Pathology
February 16, 2026
ColoSTAT commercial deployment - First physician enrolled
February 10, 2026
Rhythm Biosciences Signs Manufacturing Agreement
February 2, 2026
Quarterly Activities Report and Appendix 4C
January 22, 2026
Enhanced Genetype colorectal cancer risk test released - supports earlier disease detection and ColoSTAT® targeting
January 13, 2026
datma and Rhythm Biosciences Announce Collaboration to Apply Federated Real-World Data to Genomic Diagnostic Development
December 22, 2025
Rhythm Initiates Commercialisation of ColoSTAT
December 11, 2025
Appendix 4C and Market Update
October 28, 2025
Appendix 4E
August 29, 2025
Strategic partnership with Know Your Lemons Foundation
August 27, 2025
ColoSTAT Kit Validation Completion and NATA Submission
August 25, 2025
Placement Prospectus
August 18, 2025
Share Placement to Raise Up To $3.75 million
August 17, 2025
Placement Issue Investor Presentation
August 17, 2025
Response to ASX Price Query
August 6, 2025
ColoSTAT Kits Deliver Breakthrough Results
August 3, 2025
Jun 25 Quarterly Activities Report and Appendix 4C
July 30, 2025
FY2025 R&D Tax Incentive Loan Funding
June 30, 2025
NATA Accreditation Awarded for Genetype Laboratory
June 23, 2025
ColoSTAT Beta kit verification and validation update
May 25, 2025
Breast Cancer Risk Study University of Melbourne
May 14, 2025
Quarterly Activities Report and Appendix 4C 31 March 2025
April 23, 2025
EGM - Investor Presentation
March 30, 2025
RHY Genetype Commercial Sales
March 18, 2025
RHY Investor Webinar
March 4, 2025
Genetype Commercial Integration Completion
February 3, 2025
Quarterly Activities Report and Appendix 4C - Dec24
January 22, 2025
About the Genetype Acquisition
January 13, 2025
Completion of Genetype Risk Assessment Portfolio Acquisition
December 23, 2024
RHY Acquires Genetype Genetic Risk Assessment Business
December 22, 2024
Pause in Trading
December 20, 2024
Market Update - All End of CY24 Milestones Attained
December 17, 2024
Strong Demand in Share Placement to Raise $3.5 million
November 18, 2024
Receipt of Research & Development Tax Incentive
November 6, 2024
2nd Generation, ColoSTAT Multiplex Alpha Kit Outperforms
October 6, 2024
Board Renewal / Composition Update
September 29, 2024
Platform Expansion - Gastric Cancer Diagnostic Test Update
September 23, 2024
Product and Market Update - Phase 2 Milestone
August 27, 2024
Jun 24 Quarterly Activities Report and Appendix 4C
July 28, 2024
Mar24 Quarterly Activities Report and Appendix 4C
April 29, 2024